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The chemokine CXCL12/stromal cell-derived factor 1 alpha has ﬁrst been described in the
immune systemwhere it functions include chemotaxis for lymphocytes andmacrophages,
migration of hematopoietic cells from fetal liver to bone marrow and the formation of large
blood vessels. Among other chemokines, CXCL12 has recently attracted much attention
in the brain as it has been shown that it can be produced not only by glial cells but also by
neurons. In addition, its receptors CXCR4 and CXCR7, which are belonging to the G protein-
coupled receptors family, are abundantly expressed in diverse brain area, CXCR4 being
a major co-receptor for human immunodeﬁciency virus 1 entry. This chemokine system
has been shown to play important roles in brain plasticity processes occurring during
development but also in the physiology of the brain in normal and pathological conditions.
For example, in neurons, CXCR4 stimulation has been shown regulate the synaptic release
of glutamate and γ-aminobutyric acid (GABA). It can also act post-synaptically by activating a
G protein activated inward rectiﬁer K+ (GIRK), a voltage-gated K channel Kv2.1 associated to
neuronal survival, and by increasing high voltage activated Ca2+ currents. In addition, it has
been recently evidenced that there are several cross-talks between the CXCL12/CXCR4–7
system and other neurotransmitter systems in the brain (such as GABA, glutamate, opioids,
and cannabinoids). Overall, this chemokine system could be one of the key players of the
neuro-immune interface that participates in shaping the brain in response to changes in
the environment.
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INTRODUCTION
The pathways by which nervous and immune systems interact
to modulate plasticity in response to changes in the environ-
ment are still a matter of debate. It has been shown that many
immune cells express receptors to neurotransmitters such as
dopamine (DA), serotonin, or acetylcholine (Franco et al., 2007).
Neurotransmitters released by nerve terminals in the blood or
in lymphoid organs could by this way inﬂuence immune cells.
Conversely, cytokines/chemokines and their receptors that were
ﬁrst described in the immune system have been recently found
in the brain, in glial cells, and neurons themselves. Indeed, fol-
lowing inﬂammation or infection, cytokines are released in the
blood. Besides their effect on the immune system, cytokines
can also act in the brain to modulate our behaviors, induc-
ing, for example, anorexia upon inﬂammation when produced
in large amount, but cytokines/chemokines could also play
a key role in the brain even in non-pathological conditions.
Cytokines/chemokines can inﬂuence the brain and the behaviors
through several possible pathways:modulating peripheral neurons
which project to the brain through the vagus nerve, modulat-
ing the levels of hormones such as leptin which can act to the
brain through the humoral pathway and acting directly in the
brain, through the local production of cytokines and chemokines
(Guyon et al., 2008a).
Among cytokines, chemokines are small proteins (7–14 kDa)
with chemoattractant properties whose main documented role
is leukocyte recruitment at inﬂammatory sites (Luster, 1998;
Ransohoff and Tani, 1998; Glabinski and Ransohoff, 1999; Rossi
and Zlotnik, 2000; Luther and Cyster, 2001; Proudfoot, 2002). At
least 50 chemokines have been found to date and they have been
classiﬁed as C, CC, CXC, and CXXXC according to the number
and spacing of the conserved cysteine residues at the N-terminal
position (Murphy et al., 2000). Phylogenic analyses showed that
the large, highly redundant CXC chemokine family is a very recent
phenomenon that is exclusive to higher vertebrates. Interestingly,
its ancestral role might be within the central nervous system
(CNS) and not within the immune system (Huising et al., 2003).
Chemokines exert their biological effects through cell surface
receptors that belong to the superfamily of seven-transmembrane
domain G protein-coupled receptors (GPCRs).
At least 22 chemokine receptors have been characterized, which
are designed following the chemokine nomenclature presented
before. Most chemokines bind to several chemokine receptors and
most chemokine receptors recognize several chemokines (Bacon
andHarrison,2000). Under ligand stimulation, receptor activation
usually activates multiple intracellular pathways and undergoes
a desensitization and internalization. Besides their role in the
immune system, chemokines and their receptors seem to play
an important role in the CNS, where they were ﬁrst detected
in immune-like competent cells (microglia and astrocytes), but
were next found in neuronal cells (for review, see Cho and Miller,
2002; Banisadr et al., 2005). Local chemokine release is commonly
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associated toneurodegenerative andneuroinﬂammatorydisorders
such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease,
and human immunodeﬁciency virus (HIV)-associated dementia
(Streit et al., 2001; Vila et al., 2001; Lee et al., 2002; McGeer and
McGeer, 2004; Cartier et al., 2005). In addition, accumulating evi-
dence show that chemokines canmodulate the electrical activity of
neurons through various mechanisms (Guyon and Nahon, 2007;
Rostene et al., 2007).
One of the most studied chemokine is the stromal cell-derived
factor 1 alpha (SDF-1α) also named CXCL12. This chemokine was
originally described as a secreted product of bone marrow stromal
cell line (Tashiro et al., 1993). Three protein isoforms, SDF-1α,
SDF-1β, and SDF-1γ, which arise from alternative mRNA splic-
ing, have been characterized (Gleichmann et al., 2000; Pillarisetti
and Gupta, 2001; Stumm et al., 2002). The SDF-1β isoform is
selectively expressed by endothelial cells of cerebral microvessels
and could be involved in cerebral inﬁltration of CXCR4-carrying
leukocytes, whereas neurons synthesize SDF-1α mRNA (Stumm
et al., 2002), and most studies have focused on SDF-1α. This
chemokine of 67 amino acids, more recently called CXCL12, was
ﬁrst believed to act on a single receptor, the CXCR4. Since then, a
second receptor has been found to be another target of CXCL12,
namelyCXCR7. Contrary toCXCR4, coupling of CXCR7 toGpro-
teins could not be demonstrated, and CXCR7 was ﬁrst believed
to be mainly involved in ligand sequestration (Thelen and The-
len, 2008). However, a recent study shows that ligand binding
to CXCR7 activates mitogen-activated protein (MAP) kinases
through beta-arrestins (Zabel et al., 2009; Rajagopal et al., 2010;
Figure 1).
In the immune system, the binding of CXCL12 to
CXCR4/CD184 induces intracellular signaling through several
divergent pathways initiating signals related to chemotaxis, cell
survival and/or proliferation, increase in intracellular calcium,
and gene transcription. CXCR4 is expressed on multiple cell types
including lymphocytes, hematopoietic stem cells, endothelial and
epithelial cells, and cancer cells. The CXCL12/CXCR4 axis is
involved in tumor progression, angiogenesis, metastasis, and sur-
vival. Besides its roles in the immune system, CXCL12 also plays a
major role in the CNS (Adler and Rogers, 2005; Figure 2).
In a ﬁrst part, we will describe the roles of this chemokine
system in the brain in pathological as well as physiological condi-
tions, and show that it is acting as a neuro-modulator. In a second
part, we will show in more detail the cross-talk of the CXCL12/
CXCR4–7 system with other neurotransmitter systems in the
brain, particularly γ-aminobutyric acid (GABA) and glutamate
systems. Finally, we will show the role of the CXCL12/CXCR4–7
system in the immune–nervous system interaction.
CXCL12 ACTIONS IN THE BRAIN
In the CNS, CXCL12 is an important chemokine playing a key
role in neurogenesis (Ma et al., 1998; Zou et al., 1998; Lu et al.,
2002) controlling axonal guidance and neurite outgrowth (Xiang
et al., 2002; Pujol et al., 2005). For example, it is established that
the future interneurons are maintained by a CXCL12/CXCR4
FIGURE 1 | CXCL12 chemokine signaling. CXCL12 acts through its
receptors CXCR4 and CXCR7. CXCR4 stimulation leads to the activation
of numerous signaling pathways depending on the cell types while
CXCR7 has mainly been shown to be involved in scavenging CXCL12,
although it can activate a MAP kinase pathway through β-arrestin in
several systems.
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FIGURE 2 | CXCL12 roles in the brain-immune system cross-talk in non-pathological and pathological conditions.
mediated attractive interaction in their tangential cortical routes
(Stumm et al., 2003; Lopez-Bendito et al., 2008; Lysko et al., 2011).
CXCL12/CXCR4 has also been shown to regulate the migration
and orientation of processes in A9–A10 dopaminergic neurons
(Yang et al., 2013). During development, CXCL12 also regulates
the migration rate of gonadotropin-releasing hormone (GnRH)
neurons (neuroendocrine cells, located in the hypothalamus, that
play an essential role in mammalian reproduction), through
CXCR4 and activation of a GIRK channel (Casoni et al., 2012).
The migration of GnRH neurons is also indirectly inﬂuenced by
CXCR7, which regulates CXCL12 availability by acting as a scav-
enger along the migratory path of these neurons (Memi et al.,
2013).
CXCL12 also plays a major role in neuro-inﬂammation as it
mediates local immune responses as well as attracting leukocytes
which are believed to migrate along a concentration gradient of
chemokine across the blood–brain barrier (BBB) to their target
(Engelhardt and Ransohoff, 2012). This occurs for example in
Alzheimer’s disease in the vicinity of the amyloid plaques that
attract and/or activate local glial cells (Xia and Hyman, 1999). As
the glycoprotein gp120 from the envelope of HIV-1 binds directly
to CXCR4 and has direct neurotoxic effects, CXCR4 is likely to be
crucial for different aspects of CNSHIV infection and the develop-
ment of AIDS dementia, and CXCL12 could have neuroprotective
effects in this context as well as in other forms of damage.
Aside from a role in CNS development and pathology, con-
stitutive expression of CXCL12 and its receptor CXCR4 has been
demonstrated in different cell types of the adult brain includ-
ing endothelial, glial, and notably neuronal cells (Ohtani et al.,
1998; Bajetto et al., 1999a; Lazarini et al., 2000; Stumm et al.,
2002; Banisadr et al., 2003, 2004; Bonavia et al., 2003; Heinisch
and Kirby, 2010). In situ hybridization and immunocytochem-
istry showed that CXCR4 neuronal expression was found in
many different brain areas, notably cerebral cortex, globus pal-
lidus, caudate putamenand substantia innominata (Banisadr et al.,
2002), supraoptic and paraventricular hypothalamic nuclei (Ban-
isadr et al., 2003), lateral hypothalamus (LHA; where CXCR4 is
co-localized with neurons expressing the melanin-concentrating
hormone (MCH; Guyon et al., 2005a), ventromedial thalamic
nucleus and substantia nigra (SN; where CXCR4 is expressed on
dopaminergic neurons of the pars compacta; Banisadr et al., 2002),
but also onGABAergic neurons of the pars reticulata (Guyon et al.,
2006), in the dorsal raphe nucleus (in serotoninergic and non-
serotoninergic neurons (Heinisch and Kirby, 2010)) and in the
cerebellum (where it is expressed both in Purkinje neurons and
granule cells and in glial radial ﬁbers; Ragozzino, 2002). Thus,
CXCL12 and CXCR4 proteins were found co-expressed in a num-
ber of brain regions andmuchevidence suggest that they constitute
together a functional receptor/ligand system in speciﬁc neuronal
pathway.
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CXCR4 stimulation by CXCL12 activates pertussis toxin
(PTX)-sensitive G proteins which activate at least two
distinct signaling pathways. The ﬁrst pathway, involving
phosphatidylinositol-3 (PI-3) kinase and extracellular signal-
regulated kinase (ERK)1/2, has been described in rodent astro-
cytes, neuronal progenitors, and cortical neurons (Bacon and
Harrison, 2000; Lazarini et al., 2000; Bajetto et al., 2001; Bonavia
et al., 2003). The other pathway involves the phospholipase Cβ
whose activation leads to an increase in the intracellular calcium
in astrocytes, cortical neurons, and cerebellar granule cell, aswell as
in primate fetal neuron and microglia (Bajetto et al., 1999b; Klein
et al., 1999; Zheng et al., 1999). The increase in calcium leads to the
activation of proline-rich tyrosine kinase (PYK2), whichmay itself
lead to ERK1/2 activation (Bajetto et al., 2001). CXCR4 stimula-
tion can directlymodulate ionic channels of the plasmamembrane
in neurons, particularly high-threshold calcium channels (Guyon
et al., 2008b), and this could also result in intracellular calcium
increase and PYK2 activation (Lazarini et al., 2003). Finally, in pri-
mary cultures of neurons, CXCR4 can also inhibit cAMP pathways
through the Gi component of GPCRs (Liu et al., 2003).
The neuromodulatory actions of CXCL12 have been found in
various neuronal populations (including CA1 neurons of the hip-
pocampus, granular and Purkinje cells of the cerebellum, MCH
neurons of the LHA, vasopressinergic neurons of the supraoptic
and the paraventricular nucleus of the hypothalamus, dopamin-
ergic neurons of the SN, serotoninergic and non-serotoninergic
neurons of the dorsal raphe nucleus; Limatola et al., 2000;
Ragozzino, 2002; Guyon et al., 2005a,b, 2008b; Callewaere et al.,
2006; Heinisch and Kirby, 2010).
CXCR4 activation by its ligand can modulate neuronal activity
through multiple regulatory pathways including and often com-
bining: (i) modulation of voltage-dependent channels (sodium,
potassium, and calcium; Limatola et al., 2000; Guyon et al., 2005b),
(ii) activation of the GIRK channels, (iii) increase in neuro-
transmitter release (GABA, glutamate, DA), often via calcium-
dependent mechanisms (Guyon and Nahon, 2007). From one
structure to another, CXCL12 has often similar consequences
on neuronal transmembrane currents, but through different
mechanisms.
CXCL12 has pre-synaptic actions, which are similar in the differ-
ent brain structures where it has been tested, increasing glutamate
and/orGABA synaptic activities in LHA (Guyon et al., 2005a), hip-
pocampus (Zheng et al., 1999), cerebellum (Limatola et al., 2000),
SN (Guyon et al., 2006), and dorsal raphe nucleus (Heinisch and
Kirby, 2010). However, the mechanisms of action of CXCL12 vary
from one structure to the other: for example, the increase in fre-
quency of GABA typeA (GABAA) post-synaptic events in response
to CXCL12 occurs through an indirect mechanism involving glu-
tamate release in the cerebellum (Limatola et al., 2000) and the
serotoninergic neurons of the raphe nucleus (Heinisch and Kirby,
2010), while the effect is direct through CXCR4 of dopaminergic
neurons in the SN (Guyon et al., 2006). Similarly, the glutamate
release is tetrodotoxin (TTX) dependent in the LHA (Guyon et al.,
2005a) and in the raphe (Heinisch and Kirby, 2010), while it is
TTX independent in the SN (Guyon et al., 2006).
The target effects on the post-synaptic neurons also vary
depending on the structure and the neuronal population. For
example, the CXCL12-induced increase in GABA release in the
LHA evokes a tonic GABAA current in MCH-expressing neu-
rons (Guyon et al., 2005a), opposite to what is observed in DA
neurons in which GABA type B (GABAB) receptor stimulation
following GABA spillover activates a GIRK current (Guyon et al.,
2006). This could be due to various subunit compositions of
the GABAA receptor expressed in the two neuronal populations,
with different kinetics, and/or different subcellular localization
of the GABAA/B/CXCR4 receptors and GIRK channels. Inter-
estingly, in MCH neurons, CXCL12 also induced the activation
of a GIRK current, but this happened directly through CXCR4
stimulation.
In the dorsal raphe nucleus, CXCR4 stimulation by CXCL12
stimulates spontaneous inhibitory post-synaptic potential (sIPSC)
frequency, by a pre-synaptic mechanism on 5HT-neurons, but
it acts on sIPSC amplitude by a post-synaptic mechanism in
non-5HT neurons (Heinisch and Kirby, 2010). Finally, CXCR4
stimulation is able to modulate various voltage-dependent chan-
nels: Na+ andK+ channels of the actionpotential inMCHneurons
(Guyon et al., 2005b) and high voltage activated (HVA) Ca chan-
nels, in particular of the N-type, in DA neurons of the SN (Guyon
et al., 2008b) and in pre-synaptic glutamatergic terminals of the
hippocampus (Zheng et al., 1999).
In conclusion, fromone structure to another, CXCL12has often
similar consequences on neuronal transmembrane currents, but
through different mechanisms.
Therefore, the CXCL12/CXCR4–7 system exerts neuromodu-
latory functions in the normal brain.
CROSS-TALK WITH OTHER NEUROTRANSMITTER SYSTEMS
CROSS-TALK WITH GABAergic SYSTEM
γ-Aminobutyric acid is the major inhibitory neurotransmitter
in the adult nervous system but it also plays important roles
in CNS development by regulating neurogenesis and synapto-
genesis (LoTurco et al., 1995; Somogyi et al., 1995). In contrast
to its inhibitory actions on adult neurons, GABA is capable of
depolarizing neuronal progenitor cells and immature neurons
(Ben-Ari, 2002; Rheims et al., 2008) and participates in formation
of a primitive network-driven pattern of electrical activity called
the giant depolarizing potentials (GDPs), an electrical circuit
pattern critical to generate large oscillations of intracellular cal-
cium for activity-dependent modulation of neuronal growth and
synapse formation (Ben-Ari,2002). HIV-1 gp120,whichbinds and
stimulates CXCR4, enhances GDPs in neonatal rat hippocampus
(Kasyanov et al., 2006), underlying the role played by CXCR4 in
the developmental process. Moreover, the developmental function
of GABA is in part regulated byGABAproduction, a processmedi-
ated by glutamic acid decarboxylases (GADs), the key rate-limiting
enzymes for synthesis of GABA. Two GAD isoforms, GAD65 and
GAD67, are expressed in the adult nervous system (Erlander et al.,
1991). It has been shown that CXCL12/CXCR4 signaling, via
ERKs and the transcription factor Egr1, induces expression of
GAD67 in embryonic hippocampal cultured neurons, a mecha-
nism which may promote the maturation of GABAergic neurons
during development (Luo et al., 2008).
In adult brain, as previously mentioned, CXCL12, through
CXCR4, is also able to modulate pre-synaptic GABA release
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(Limatola et al., 2000; Guyon et al., 2006; Heinisch and Kirby,
2010). GABA acts post-synaptically through its receptors. GABAA
receptors are ionotropic receptors permeant to chloride. As
CXCR4, GABAB receptors are GPCRs that mediate metabotropic
action of GABA and are located on neurons and immune cells
as well. Using diverse approaches, a novel interaction between
CXCR4 andGABA/GABAB receptor agonists/antagonists has been
recently reported, which was revealed to be an allosteric action of
these agents on CXCR4 (Guyon et al., 2013). This result came
ﬁrst from the observation that GABAB antagonists and agonists
and even GABA itself blocked CXCL12-elicited chemotaxis in
human breast cancer cells, and that a GABAB antagonist blocked
the potentiation by CXCL12 of high threshold Ca+2 channels
in Rat dopaminergic neurons (Guyon et al., 2013). CXCR4 and
GABAB often co-express in the same cell type (Banisadr et al.,
2002), have complementary functionality and may be involved
in cross-talk (Duthey et al., 2010). CXCR4 and GABAB recep-
tor could have interacted directly through heterodimerization.
Indeed, heterodimerization is known to play a role in signal trans-
duction of other metabotropic receptors, for example, GABAB
receptors interact with metabotropic glutamate receptors (Hirono
et al., 2001). Following CXCL12 interaction, CXCR4 undergoes
a homo-dimerization which is necessary for its functionality
and signaling (Mellado et al., 2001; Toth et al., 2004). Dimer-
ization, which is accompanied by receptor phosphorylation as
well as changes in signal transduction processes (Rodriguez-
Frade et al., 2001), enables the activation of the JAK/STAT (Janus
kinase/signal transducers and activators of transcription ) pathway
which allows the subsequent triggering of G protein-dependent
signaling events (Vila-Coro et al., 1999). CXCR4 could also form
heterodimers with other GPCRs, which could lead to complex
responses according to the chemokines/peptides/neuromediator
environment present in the extracellular medium. For example,
CXCR4 has been shown to form heterodimers with CCR2 and
CCR5, delta opioid receptors and CXCR7 (Percherancier et al.,
2005; Pello et al., 2008; Levoye et al., 2009; Sohy et al., 2009).
However, by co-expressing in the membrane of Xenopus oocytes
GABAB receptors tagged with Td tomato (red ﬂuorophore)
and CXCR4 receptors tagged with green ﬂuorescent protein
(GFP), data obtained in total internal reﬂection ﬂuorescence
(TIRF) microscopy showed that CXCR4 and GABAB receptors
did not co-localize in the membrane (A. Guyon, unpublished
data).
γ-Aminobutyric acid and the agonists/antagonists of GABAB
receptors were recently found to act directly on CXCR4 in an
allosteric manner (Figure 3A). Using electrophysiology in Xeno-
pus oocytes and human embryonic kidney (HEK293) cells in
which Rat CXCR4 and the GIRK channel were co-expressed, it
could be demonstrated thatGABAB antagonist and agonistmodify
the CXCL12-evoked activation of GIRK channels (Figures 3B,C;
Guyon et al., 2013). By expressing CXCR4 receptors in heterol-
ogous systems lacking GABAB receptors and performing com-
petition binding experiments it could be investigated whether
GABAB ligands bind to CXCR4. FRET experiments suggested
that GABAB ligands do not bind CXCR4 at the CXCL12 binding
pocket suggesting allosteric modulation, in accordance with elec-
trophysiology data (Guyon et al., 2013). Finally, back-scattering
interferometry (BSI) on lipoparticles containing only the CXCR4
receptor allowed to quantify the binding afﬁnity for the GABAB
ligands (including GABA), which were in a similar range to the
afﬁnity of the ligands for GABAB receptors themselves, thus con-
ﬁrming that GABA and GABAB receptor ligands directly interact
allosterically with the CXCR4 receptor (Figure 3D; Guyon et al.,
2013).
As mentioned previously, CXCR4 activation by CXCL12
increases pre-synaptic neurotransmitter release and particularly
GABA release in several neuronal populations (Guyon and Nahon,
2007; Bhattacharyya et al., 2008; Qu et al., 2008). If GABA can in
turn block the effects of CXCL12, this could represent a negative
feedback loop for pre-synaptic chemokine release. Indeed, when
applying CXCL12 for several minutes, a transient increase in the
frequency of sIPSCs is frequently observed, followed by a reduced
activity (see Figure 3 in Guyon et al., 2006). This reduction could
be due to an antagonistic effect of GABA, although desensitization
of CXCR4 itself cannot be excluded. Similarly, it has been shown
that elevated concentrations of CXCL12 exert opposite effect
than lower concentrations on the electrical activity of some neu-
ronal populations that receive GABA inputs (Guyon and Nahon,
2007). The antagonistic effect of GABA released pre-synaptically
in response to CXCL12 could contribute to these biphasic effects.
In the future, it will be of interest to search for putative effects
of GABAB receptor ligands on CXCR7, the other receptor for
CXCL12. In addition, the effect of GABAergic agents on CXCR4
suggests new therapeutic potentials for neurological and immune
diseases.
CROSS-TALK WITH GLUTAMATERGIC SYSTEMS
Glutamate is the main excitatory neurotransmitter in the adult
brain. CXCL12/CXCR4 also plays a major role in the regulation of
crucial components of glutamatergic transmission.
The chemokine CXCR4 receptor is a GPCR widely expressed
on glial cells (especially astrocytes and microglia). Activation
of the astrocytic CXCR4 by CXCL12 results in a long chain of
intracellular and extracellular events [including the release of the
pro-inﬂammatory cytokine tumor necrosis factor alpha (TNF-α)
and prostanglandins] leading to glutamate release (Cali et al.,
2008; Cali and Bezzi, 2010). Similarly, and as previously men-
tioned, CXCL12/CXCR4 increases glutamate release from neurons
in different structures including LHA (Guyon et al., 2005a), hip-
pocampus (Zheng et al., 1999), cerebellum (Limatola et al., 2000),
SN (Guyon et al., 2006), and dorsal raphe nucleus (Heinisch and
Kirby, 2010).
In addition, recent studies showed that CXCL12 protects
cortical neurons from excitotoxicity by promoting the func-
tion of the gene-repressor protein Rb, which is involved in the
recruitment of chromatin modiﬁers [such as histone deacetylases
(HDACs)] to gene promoters. In neurons, Rb controls activity-
dependent genes essential to neuronal plasticity and survival,
such as the N-methyl-D-aspartic acid (NMDA) receptor’s sub-
unit NR2B (Khan et al., 2008), the expression of which in the
tetrameric ion channel largely affects calcium signaling by glu-
tamate. CXCL12 selectively inhibits NR2B expression in vitro
and in vivo altering NMDA-induced calcium responses associ-
ated with neuronal death, while promoting prosurvival pathways
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FIGURE 3 | GABA and agonists/antagonists of the GABAB receptor are
allosteric modulators of CXCR4. (A) Scheme showing the diverse agents
acting on the CXCR4 receptor that have been tested. CXCR4 has been
co-expressed together with GIRK channels in Xenopus oocytes and human
embryonic kidney (HEK293) cells. The activation of CXCR4 by the diverse
agent tested was evaluated by measuring the amplitude of the GIRK current
activated. (B) Results obtained in HEK293 cells expressing CXCR4 and
reporting GIRK channel.Top: Traces recorded in response to the application of
1 nM CXCL12 with or without GABA. GABA inhibits partially the CXCL12
effect and this effect is reversible upon washout of GABA. Bottom: Histogram
showing the allosteric actions of the CXCR4 antagonist AMD3100 compared
to GABA and other agonists/antagonists of GABAB receptors. (C) Results
obtained in Xenopus oocytes expressing CXCR4 and reporting GIRK channel.
Top: Traces recorded in response to the application of three increasing GABA
concentrations. Bottom:We took advantage of the agonist effect of GABA and
of the GABAB agonists/antagonists in this expression system to build their
concentration–response curve on CXCR4. (D) Back-scattering interferometry
(BSI) results obtained on lipoparticles containing only CXCR4. Left : BSI
reveals a KD of CXCL12 on its receptor of 0.49 ± 0.16 nM, which is coherent
with the EC50 measured by our electrophysiological experiments. Dopamine,
used as a negative control, does not bind to CXCR4. Right : BSI reveals that
GABA can also directly bind to CXCR4 with a KD of 0.57 ± 0.24 μM, coherent
with the EC50 measured in electrophysiology. Therefore, GABA can directly
bind to CXCR4. Adapted from Guyon et al. (2013).
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that depend on stimulation of synaptic receptors (Nicolai et al.,
2010).
CROSS-TALK WITH OTHER SYSTEMS
In the periaqueducal gray (PAG), a pretreatment with CXCL12
desensitized the analgesic effects of opioids (Szabo et al., 2002;
Chen et al., 2007) and a heterologous desensitization mecha-
nism at the GPCR level involving CXCR4 has been suggested
(Chen et al., 2007; Heinisch et al., 2011). Moreover, intermedi-
ate opioid peptides (pro-enkephalin A-derived peptides secreted
by adrenal subcapsular cell hyperplasia) have been shown to be
potent activators of CXCR7 (Ikeda et al., 2013).
In the same line, the analgesic activity of the cannabinoid ago-
nist WIN 55,212-2 in the brain can be overcome in situations in
which there are elevated levels of CXCL12 in the brain (Bena-
mar et al., 2008). There could be a functional interaction between
chemokine and cannabinoid systems in the brain as the ther-
moregulatory action of the cannabinoid agonist WIN 55,212-2
in the preoptic anterior hypothalamus can be antagonized by ele-
vated levels of CXCL12 (Benamar et al., 2009). This could explain
why conditions associated with elevated level of chemokines may
result in reduction of cannabinoid functions, as is the case with
most neuroinﬂammatory diseases (such as multiple sclerosis and
HIV encephalitis).
ROLE IN THE IMMUNE–NERVOUS SYSTEM INTERACTION
As in the context of the immune system, where low levels
of CXCL12 (100 ng/ml) are attractive, whereas higher levels
(1 mg/ml) are repulsive for T cells (Zlatopolskiy and Laurence,
2001), CXCL12 often appears to have opposite effects on neu-
ronal function depending on the concentration. For example, in
DA neurons, at low concentrations, it acts as a neuromodulator by
potentiating K+-inducedDA secretion andHVA calcium currents,
whereas at higher concentration, it decreases DA release and HVA
calcium currents. This can be paralleled to what happens in MCH
neurons of the LHA, where CXCL12 also exerts opposite effects
on the action potential discharge depending on the concentra-
tion (Guyon et al., 2005a). Several putative mechanisms for these
opposite effects, which are not mutually exclusive, are reviewed in
Guyon and Nahon (2007).
CXCL12 can act in the CNS as a classical neuromediator under
normal conditions and modulate the activity of several neuro-
endocrine networks. Low concentrations of CXCL12 exert a tonic
inhibition on MCH neurons, which are known to have a hyperpo-
larized membrane potential under basal conditions, as compared
to orexin neurons of the LHA which are in intrinsic state of mem-
brane depolarization and lack CXCR4 expression (Eggermann
et al., 2003). In addition, the CXCR4 antagonist AMD 3100 has its
own effects when applied alone which suggests that a tonic activa-
tion of CXCR4 occurs, at least in slices preparations, and that low
levels of CXCL12 are secreted under basal conditions (although
the slice preparation could also be considered as an inﬂammatory
state).
However, pathological state (altered immune response or
inﬂammation) leads to abnormal concentrations of chemokines
and/or their presence at unusual sites can be found, due to local
production by glial and/or endothelial cells and/or diffusion and
transportation through the vascular circulation. This enhanced
production of chemokines could interfere with their normal func-
tions, affect neuronal and neuro-endocrine activity and modify
the functioning of the brain, leading to pathological behaviors
and/or neurotoxicity.
Following inﬂammation, cytokines are released in the blood
and can reach the brain, as the BBB permeability is increased.
Cytokine stimulation leads to higher levels of CXCL12 and other
chemokines by activation of glial or endothelial cells which
release chemokines (Meucci et al., 1998; Ohtani et al., 1998;
Lee et al., 2002). The chemokines released can reach neurons
expressing CXCR4, bind their neuronal receptors and induce
a change in their excitability that could induce an adaptive
answer to the inﬂammation, leading to the “sickness behavior,”
characterized by depression, anorexia, and fatigue (Reichenberg
et al., 2001; Dantzer and Kelley, 2007). Given the abundance
of chemokines and their receptors in the CNS, it is not sur-
prising that perturbations of cytokines/chemokines levels during
inﬂammation are causing multiple perturbations in the brain
functions and behaviors. The effects of CXCL12 on dorsal
raphe neurons could underlie depressive symptoms frequently
observed with inﬂammation (Maes, 1999), as dysfunction of
the serotoninergic systems is implicated in depression. Simi-
larly, the effects of CXCL12 on MCH neurons which are part
of the circuits controlling feeding behavior and metabolism
(Nahon, 2006) could explain the anorexia. These symptoms
of sickness behavior are usually reversible when inﬂamma-
tion stops. However, a prolonged inﬂammation, producing
higher levels of CXCL12 could even lead to neurotoxicity
and to neuro-degenerescence (Gerashchenko and Shiromani,
2004).
GENERAL CONCLUSION
CXCL12 have recently attracted much attention because this
chemokine seems to play an important role as intermediate in
the brain between cytokines and neurons in the cascade linking
inﬂammation to adaptive behavioral changes. Convergent data
suggest that CXCL12 could also act in the CNS as a classical
neuromediator under normal conditions and could modulate the
activity of several neuroendocrine networks. However, during a
pathological state (altered immune response or inﬂammation),
elevated concentrations of CXCL12 and/or its presence at unusual
sites, due to its local production by glial and/or endothelial cells
and/or its diffusion and transportation through the vascular cir-
culation could affect neuronal and neuroendocrine activities and
modify the functioning of the brain, leading to pathological
behaviors and/or neurotoxicity. In addition, recent evidence show
that there are numerous cross-talks between CXCL12/CXCR4–7
systems and other neurotransmitter systems of the CNS, illustrat-
ing new pathways by which the CNS and immune system can
interact.
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